JP2024020436A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024020436A5 JP2024020436A5 JP2023195187A JP2023195187A JP2024020436A5 JP 2024020436 A5 JP2024020436 A5 JP 2024020436A5 JP 2023195187 A JP2023195187 A JP 2023195187A JP 2023195187 A JP2023195187 A JP 2023195187A JP 2024020436 A5 JP2024020436 A5 JP 2024020436A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- amino acid
- acid sequence
- scfv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000012804 lymphangiosarcoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020198044 | 2020-11-30 | ||
| JP2020198044 | 2020-11-30 | ||
| JP2021110912 | 2021-07-02 | ||
| JP2021110912 | 2021-07-02 | ||
| PCT/JP2021/043538 WO2022114163A1 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
| JP2022565479A JP7393774B2 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565479A Division JP7393774B2 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024020436A JP2024020436A (ja) | 2024-02-14 |
| JP2024020436A5 true JP2024020436A5 (enExample) | 2024-12-16 |
Family
ID=81754499
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565479A Active JP7393774B2 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
| JP2023195187A Pending JP2024020436A (ja) | 2020-11-30 | 2023-11-16 | Ｈｅｒ２標的化剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565479A Active JP7393774B2 (ja) | 2020-11-30 | 2021-11-29 | Ｈｅｒ２標的化剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240002531A1 (enExample) |
| EP (1) | EP4253420A4 (enExample) |
| JP (2) | JP7393774B2 (enExample) |
| KR (1) | KR20230114747A (enExample) |
| AU (1) | AU2021387127A1 (enExample) |
| CA (1) | CA3199473A1 (enExample) |
| IL (1) | IL303154A (enExample) |
| MX (1) | MX2023005864A (enExample) |
| TW (1) | TW202229359A (enExample) |
| WO (1) | WO2022114163A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2024008227A (es) * | 2022-04-08 | 2024-07-19 | Fate Therapeutics Inc | Celulas que tienen cadena principal dirigida a tumores solidos y uso de estas. |
| EP4504799A1 (en) | 2022-04-08 | 2025-02-12 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2314686T4 (da) | 2000-10-06 | 2023-08-21 | Kyowa Kirin Co Ltd | Celler, der danner antistofsammensætninger |
| ES2527143T3 (es) * | 2009-12-07 | 2015-01-20 | Fundació Privada Institució Catalana De Recerca I Estudis Avançants | Anticuerpos frente a variante truncada CTF-611 de HER2 |
| US9243057B2 (en) * | 2010-08-31 | 2016-01-26 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| WO2019246021A1 (en) * | 2018-06-18 | 2019-12-26 | Dxdiscovery, Inc. | Methods and compositions for pertussis diagnosis |
| EP4504799A1 (en) * | 2022-04-08 | 2025-02-12 | Fate Therapeutics, Inc. | Chimeric antigen receptor for tumor targeting |
-
2021
- 2021-11-29 EP EP21898135.5A patent/EP4253420A4/en active Pending
- 2021-11-29 WO PCT/JP2021/043538 patent/WO2022114163A1/ja not_active Ceased
- 2021-11-29 CA CA3199473A patent/CA3199473A1/en active Pending
- 2021-11-29 MX MX2023005864A patent/MX2023005864A/es unknown
- 2021-11-29 KR KR1020237017469A patent/KR20230114747A/ko active Pending
- 2021-11-29 US US18/038,185 patent/US20240002531A1/en active Pending
- 2021-11-29 AU AU2021387127A patent/AU2021387127A1/en active Pending
- 2021-11-29 TW TW110144472A patent/TW202229359A/zh unknown
- 2021-11-29 IL IL303154A patent/IL303154A/en unknown
- 2021-11-29 JP JP2022565479A patent/JP7393774B2/ja active Active
-
2023
- 2023-08-04 US US18/365,828 patent/US11981747B1/en active Active
- 2023-11-16 JP JP2023195187A patent/JP2024020436A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022101693A5 (enExample) | ||
| JP2013502913A5 (enExample) | ||
| JP2015509947A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2024020436A5 (enExample) | ||
| JP2007515165A5 (enExample) | ||
| JP2020522488A5 (enExample) | ||
| JP2025069432A5 (enExample) | ||
| IL276675B1 (en) | Anti-pd-1 antibodies and uses thereof | |
| Yang et al. | A novel anti-p21Ras scFv antibody reacting specifically with human tumour cell lines and primary tumour tissues | |
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| JPWO2021251459A5 (enExample) | ||
| CN115916839A (zh) | 抗pdl1×egfr的双特异性抗体 | |
| JPWO2022114163A5 (enExample) | ||
| JPWO2021170068A5 (enExample) | ||
| JPWO2019210848A5 (enExample) | ||
| JPWO2022067262A5 (enExample) | ||
| JPWO2020081928A5 (enExample) | ||
| JPWO2021247769A5 (enExample) | ||
| JPWO2022159984A5 (enExample) | ||
| CN115279791A (zh) | 靶向her2的抗原结合构建体及用途 | |
| JPWO2021190622A5 (enExample) | ||
| JPWO2021068841A5 (enExample) | ||
| JPWO2023051683A5 (enExample) | ||
| JPWO2022068854A5 (enExample) |